Quantinno Capital Management LP Purchases 30,816 Shares of Xenon Pharmaceuticals Inc. $XENE

Quantinno Capital Management LP boosted its position in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE) by 125.1% in the first quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 55,444 shares of the biopharmaceutical company’s stock after acquiring an additional 30,816 shares during the quarter. Quantinno Capital Management LP owned 0.06% of Xenon Pharmaceuticals worth $3,224,000 at the end of the most recent reporting period.

A number of other institutional investors also recently bought and sold shares of the company. Danske Bank A S bought a new stake in shares of Xenon Pharmaceuticals during the 3rd quarter valued at about $32,000. Blue Trust Inc. increased its position in shares of Xenon Pharmaceuticals by 2,560.7% during the 4th quarter. Blue Trust Inc. now owns 745 shares of the biopharmaceutical company’s stock valued at $33,000 after purchasing an additional 717 shares during the last quarter. Kestra Advisory Services LLC bought a new position in shares of Xenon Pharmaceuticals in the 4th quarter worth approximately $33,000. Osaic Holdings Inc. lifted its stake in shares of Xenon Pharmaceuticals by 541.4% in the 2nd quarter. Osaic Holdings Inc. now owns 1,225 shares of the biopharmaceutical company’s stock worth $40,000 after purchasing an additional 1,034 shares during the period. Finally, Caitong International Asset Management Co. Ltd purchased a new position in shares of Xenon Pharmaceuticals in the fourth quarter worth approximately $43,000. Institutional investors own 95.45% of the company’s stock.

Insider Transactions at Xenon Pharmaceuticals

In other news, Director Gillian Cannon sold 1,190 shares of the company’s stock in a transaction dated Friday, June 5th. The stock was sold at an average price of $53.14, for a total value of $63,236.60. Following the completion of the transaction, the director owned 1,455 shares of the company’s stock, valued at $77,318.70. This represents a 44.99% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Gary Patou sold 1,322 shares of the stock in a transaction dated Friday, June 5th. The stock was sold at an average price of $53.14, for a total value of $70,251.08. Following the sale, the director owned 24,896 shares of the company’s stock, valued at $1,322,973.44. This represents a 5.04% decrease in their position. The SEC filing for this sale provides additional information. 2.91% of the stock is owned by company insiders.

Xenon Pharmaceuticals Price Performance

Shares of NASDAQ XENE opened at $63.36 on Friday. The firm has a fifty day moving average price of $60.24 and a 200-day moving average price of $54.20. The stock has a market cap of $6.13 billion, a PE ratio of -13.37 and a beta of 0.62. Xenon Pharmaceuticals Inc. has a 1 year low of $32.78 and a 1 year high of $72.66.

Xenon Pharmaceuticals (NASDAQ:XENE) last released its earnings results on Thursday, August 6th. The biopharmaceutical company reported ($1.11) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.16) by $0.05. During the same quarter in the previous year, the firm posted ($1.07) EPS. On average, research analysts expect that Xenon Pharmaceuticals Inc. will post -4.92 EPS for the current year.

Analyst Ratings Changes

XENE has been the subject of several recent research reports. Needham & Company LLC reduced their target price on shares of Xenon Pharmaceuticals from $80.00 to $78.00 and set a “buy” rating for the company in a report on Friday, May 8th. JPMorgan Chase & Co. lifted their price target on shares of Xenon Pharmaceuticals from $80.00 to $82.00 and gave the stock an “overweight” rating in a research note on Wednesday, May 27th. Wall Street Zen raised shares of Xenon Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Saturday, August 1st. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Xenon Pharmaceuticals in a report on Monday, July 6th. Finally, Wells Fargo & Company reissued an “overweight” rating and set a $69.00 price target on shares of Xenon Pharmaceuticals in a report on Sunday, May 10th. Two research analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average target price of $77.13.

Xenon Pharmaceuticals News Roundup

Here are the key news stories impacting Xenon Pharmaceuticals this week:

• Positive Sentiment: Azetukalner NDA filing remains on track: Following an FDA meeting, RBC said Xenon still expects to submit a New Drug Application for azetukalner later this quarter. The filing is a major near-term catalyst for the company’s lead product candidate. Xenon Pharmaceuticals’ Azetukalner NDA Filing Remains on Track After FDA Meeting, RBC Says
• Positive Sentiment: Quarterly loss beat expectations: Xenon reported a second-quarter adjusted loss of $1.11 per share, narrower than analysts’ expected $1.16 loss. Management also said its cash position should fund operations into 2029, reducing immediate financing and dilution concerns. XENE’s Q2 Loss Narrower Than Expected, Sales Nil, Pipeline in Focus
• Neutral Sentiment: Pipeline remains the investment focus: Xenon has no reported product sales, so valuation depends largely on azetukalner’s clinical and regulatory progress. The company’s earnings call emphasized development plans and the anticipated NDA submission rather than near-term commercial revenue. Xenon Pharmaceuticals Q2 2026 Earnings Call Transcript
• Negative Sentiment: Losses continue to widen year over year: Although the quarterly loss beat estimates, the reported per-share loss was worse than the $1.07 loss recorded in the same period last year. With sales still nil and the company continuing to fund research and development, investors remain sensitive to execution and regulatory risks. Xenon Pharmaceuticals Q2 Loss Widens

Xenon Pharmaceuticals Company Profile

Xenon Pharmaceuticals Inc is a clinical?stage biopharmaceutical company dedicated to discovering and developing novel, small?molecule drugs targeting ion channels in the central and peripheral nervous system. The company’s research focus centers on neurological and pain disorders—including epilepsy, migraine, and neuropathic pain—by modulating key ion?channel proteins to restore normal neuronal function. Xenon’s scientific platform draws upon advances in ion?channel biology and structure?based drug design to identify and optimize therapeutic candidates with the potential for improved safety and efficacy profiles compared with existing treatments.

The company’s pipeline comprises multiple preclinical and clinical programs.